open access

Vol 5, No 4 (2016)
Case reports
Published online: 2016-11-03
Get Citation

Insulin sparing effect of hydroxychloroquine in uncontrolled diabetes mellitus

Mahesh Virayya Padsalge, Mahesh Vasant Abhyankar, Suraj Atmaram Ghag
DOI: 10.5603/DK.2016.0024
·
Clinical Diabetology 2016;5(4):138-140.

open access

Vol 5, No 4 (2016)
Case reports
Published online: 2016-11-03

Abstract

Hydroxychloroquine (HCQ) has a favorable glycemic effect that provides a rationale for its use in diabetes mellitus. Decreased insulin degradation and increased insulin sensitivity is suggested to contribute to the reduction in serum glucose levels. Herein, we present a case on the beneficial impact of HCQ on glycemic control in diabetes mellitus. A 69-year old female suffering from type 2 diabetes mellitus presented to the clinic for routine follow up. For management of diabetes she was taking glimepiride 4mg once daily, combination of metformin and sitagliptin (1000/50 mg) twice daily and 94 units of insulin/day. Baseline fasting plasma glucose (FPG) and postprandial plasma glucose (PPG) levels were 183 and 222 mg/dL respectively and glycosylated hemoglobin A (HbA1c) level was 8.4%. To achieve glycemic control HCQ 400 mg once daily was initiated as an add on antidiabetic drug. HBA1c level decreased to 6.9% at four months and to 6.8% at eight months after HCQ was utilized. FPG level decreased to 110 mg/dL at six months and to 114 mg/dL at eight months. PPG level decreased to 178 mg/dL at six months and 130 mg/dL at eight months. Thus the FPG level decreased by 69 mg/dL and PPG level decreased by 92 mg/dL respectively from baseline. Acknowledging the progressive positive response to antidiabetic agents, the insulin dose was decreased to 56 units/day at four months, 42 units/day at six months and 28 units/day at eight months. The case highlights the potential ability of HCQ to lower HbA1c and decrease insulin requirement in uncontrolled diabetic patients.

Abstract

Hydroxychloroquine (HCQ) has a favorable glycemic effect that provides a rationale for its use in diabetes mellitus. Decreased insulin degradation and increased insulin sensitivity is suggested to contribute to the reduction in serum glucose levels. Herein, we present a case on the beneficial impact of HCQ on glycemic control in diabetes mellitus. A 69-year old female suffering from type 2 diabetes mellitus presented to the clinic for routine follow up. For management of diabetes she was taking glimepiride 4mg once daily, combination of metformin and sitagliptin (1000/50 mg) twice daily and 94 units of insulin/day. Baseline fasting plasma glucose (FPG) and postprandial plasma glucose (PPG) levels were 183 and 222 mg/dL respectively and glycosylated hemoglobin A (HbA1c) level was 8.4%. To achieve glycemic control HCQ 400 mg once daily was initiated as an add on antidiabetic drug. HBA1c level decreased to 6.9% at four months and to 6.8% at eight months after HCQ was utilized. FPG level decreased to 110 mg/dL at six months and to 114 mg/dL at eight months. PPG level decreased to 178 mg/dL at six months and 130 mg/dL at eight months. Thus the FPG level decreased by 69 mg/dL and PPG level decreased by 92 mg/dL respectively from baseline. Acknowledging the progressive positive response to antidiabetic agents, the insulin dose was decreased to 56 units/day at four months, 42 units/day at six months and 28 units/day at eight months. The case highlights the potential ability of HCQ to lower HbA1c and decrease insulin requirement in uncontrolled diabetic patients.

Get Citation

Keywords

hydroxychloroquine, diabetes mellitus, insulin, hyperglycemia, HbA1c

About this article
Title

Insulin sparing effect of hydroxychloroquine in uncontrolled diabetes mellitus

Journal

Clinical Diabetology

Issue

Vol 5, No 4 (2016)

Pages

138-140

Published online

2016-11-03

DOI

10.5603/DK.2016.0024

Bibliographic record

Clinical Diabetology 2016;5(4):138-140.

Keywords

hydroxychloroquine
diabetes mellitus
insulin
hyperglycemia
HbA1c

Authors

Mahesh Virayya Padsalge
Mahesh Vasant Abhyankar
Suraj Atmaram Ghag

Important: This website uses cookies.tanya dokter More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Diabetologia Kliniczna dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl